The PPAR alpha-humanized mouse: a model to investigate species differences in liver toxicity mediated by PPAR alpha.
To determine the impact of the species difference between rodents and humans in response to peroxisome proliferators (PPs) mediated by peroxisome proliferator-activated receptor (PPAR)alpha, PPAR alpha-humanized transgenic mice were generated using a P1 phage artificial chromosome (PAC) genomic clone bred onto a ppar alpha-null mouse background, designated hPPAR alpha PAC. In hPPAR alpha PAC mice, the human PPAR alpha gene is expressed in tissues with high fatty acid catabolism and induced upon fasting, similar to mouse PPAR alpha in wild-type (Wt) mice. Upon treatment with the PP fenofibrate, hPPAR alpha PAC mice exhibited responses similar to Wt mice, including peroxisome proliferation, lowering of serum triglycerides, and induction of PPAR alpha target genes encoding enzymes involved in fatty acid metabolism in liver, kidney, and heart, suggesting that human PPAR alpha (hPPAR alpha) functions in the same manner as mouse PPAR alpha in regulating fatty acid metabolism and lowering serum triglycerides. However, in contrast to Wt mice, treatment of hPPAR alpha PAC mice with fenofibrate did not cause significant hepatomegaly and hepatocyte proliferation, thus indicating that the mechanisms by which PPAR alpha affects lipid metabolism are distinct from the hepatocyte proliferation response, the latter of which is only induced by mouse PPAR alpha. In addition, a differential regulation of several genes, including the oncogenic let-7C miRNA by PPs, was observed between Wt and hPPAR alpha PAC mice that may contribute to the inherent difference between mouse and human PPAR alpha in activation of hepatocellular proliferation. The hPPAR alpha PAC mouse model provides an in vivo platform to investigate the species difference mediated by PPAR alpha and an ideal model for human risk assessment PPs exposure.
Yang
Qian
Q
Laboratory of Metabolism, National Cancer Institute, National Institutes of Health, Bethesda, Maryland 20892, USA.
Nagano
Tomokazu
T
Shah
Yatrik
Y
Cheung
Connie
C
Ito
Shinji
S
Gonzalez
Frank J
FJ
D000818:Animals; D000963:Antimetabolites; D015152:Blotting, Northern; D001973:Bromodeoxyuridine; D049109:Cell Proliferation / Q000187:drug effects; D056486:Chemical and Drug Induced Liver Injury / Q000473:pathology*; D022222:Chromosomes, Artificial, Human / Q000235:genetics; D003001:Cloning, Molecular; D011345:Fenofibrate / Q000494:pharmacology; D006801:Humans; D000960:Hypolipidemic Agents / Q000494:pharmacology; D008055:Lipids / Q000097:blood; D051379:Mice; D008822:Mice, Transgenic; D008930:Mitochondria, Liver / Q000378:metabolism; D008954:Models, Biological; D047493:PPAR alpha / Q000502:physiology*; D012313:RNA / Q000096:biosynthesis; D020133:Reverse Transcriptase Polymerase Chain Reaction; D013045:Species Specificity
D000963:Antimetabolites; D000960:Hypolipidemic Agents; D008055:Lipids; D047493:PPAR alpha; D012313:RNA; D001973:Bromodeoxyuridine; D011345:Fenofibrate
Mol Pharmacol. 2005 Apr;67(4):1257-67
15635043
Physiol Genomics. 2003 Sep 29;15(1):9-19
12851464
Toxicol Sci. 2005 Nov;88(1):250-64
16081524
Carcinogenesis. 1997 Nov;18(11):2029-33
9395198
Cancer Res. 1999 Oct 1;59(19):4776-80
10519382
Proc Natl Acad Sci U S A. 2004 Mar 2;101(9):2999-3004
14973191
FEBS Lett. 1998 Jul 3;430(3):227-30
9688544
Mol Cell Biol. 1995 Jun;15(6):3012-22
7539101
Mol Cell Biol. 2007 Jun;27(12):4238-47
17438130
Gene Expr. 2001;9(6):291-304
11764000
J Cell Biochem Suppl. 2000;34:61-6
10762016
Curr Med Chem. 2003 Feb;10(4):267-80
12570700
Biochem J. 1982 Apr 1;203(1):161-8
7103935
Mol Pharmacol. 2005 Mar;67(3):681-94
15576629
Toxicol Pathol. 2005;33(1):181-4
15805070
Biochem Biophys Res Commun. 2002 Jan 25;290(3):1114-22
11798191
Crit Rev Toxicol. 2003;33(6):655-780
14727734
Biochemistry. 1993 Jun 1;32(21):5598-604
7684926
J Lipid Res. 1997 Sep;38(9):1851-8
9323594
Toxicol Sci. 1999 Jan;47(1):1-8
10048147
Cancer Lett. 1999 Aug 23;143(1):87-94
10465342
Cancer Res. 2004 Jun 1;64(11):3849-54
15172993
J Mol Med (Berl). 2005 Oct;83(10):774-85
15976920
Am J Pathol. 2000 Jun;156(6):2149-57
10854235
J Biol Chem. 2000 Sep 1;275(35):27117-22
10852923
Nature. 1980 Jan 24;283(5745):397-8
6766207
Toxicol Lett. 1998 Dec 28;102-103:85-90
10022237
Regul Toxicol Pharmacol. 1998 Feb;27(1 Pt 2):47-60
9618323
Science. 1975 Nov 21;190(4216):787-9
1198095
Toxicol Appl Pharmacol. 2002 Dec 15;185(3):180-96
12498735
Atherosclerosis. 1996 Jul;124 Suppl:S29-37
8831913
Toxicol Pathol. 2004 Jul-Aug;32 Suppl 2:6-11
15503658
Proc Natl Acad Sci U S A. 1976 Jun;73(6):2043-6
180535
Carcinogenesis. 2006 May;27(5):1074-80
16377806
Annu Rev Med. 2002;53:409-35
11818483
Carcinogenesis. 2007 Jun;28(6):1171-7
17331954